Tocagen Inc.’s shares fell nearly 80 percent after the company’s experimental treatment failed to extend life of brain cancer patients in a study, the latest in a series of setbacks for patients awaiting new treatment options for the condition.

Synchronicity Pharma announced the publication of new preclinical research demonstrating that the modulation of circadian clock components may provide a novel therapeutic approach for treating glioblastoma, the most common form of brain cancer.

Published research shows promise in using Sanofi’s multiple sclerosis drug Aubagio in addition to targeted cancer therapy to treat the aggressive brain cancer glioblastoma.

AbbVie halted the Phase III INTELLANCE-1 trial of depatuxizumab mafodotin in patients with newly diagnosed glioblastoma whose tumors have epidermal growth factor receptor amplification.

Genentech, a member of the Roche Group, announced that the U.S. FDA granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease).

Amgen, in partnership with Allergan, announced that the U.S. Food and Drug Administration approved its biosimilar for Genentech’s Avastin. The biosimilar Mvasi (bevacizumab-awwb) was approved for a broad swath of cancer indications.

Financial concerns continue to plague ImmunoCellular Therapeutics as the company continues to look for cost-cutting measures that will provide enough resources to fund continued R&D on the company’s Stem-to-T-Cell research program.